Private Venture Partners

Marcin Słomski serves as Managing Partner and appears to be the sole investment decision-maker. He holds board seats at portfolio companies, indicating a direct governance role post-closing. His background includes an INSEAD executive qualification and FCCA accounting fellowship.

Specific sourcing channels are not publicly detailed, but the firm's origins in Słomski's prior ventures — including the sale of Avenir Medical Poland to PVP — suggest a network-driven, founder-to-founder origination model. His INSEAD alumni network and ACCA membership in Poland may provide additional proprietary access.

The firm's stated strategy covers growth capital and business succession transactions in private Polish companies. The dual focus suggests mature, cash-flowing businesses rather than early-stage startups, though no stage-specific AUM breakdown exists.

The firm is classified as an asset manager, not a family office. However, the concentrated authority vested in a single managing partner and the firm's quiet public profile give it characteristics of a founder-led principal investment vehicle.

Available public records only confirm direct equity investments with post-closing board representation. There is no evidence of fund commitments, LP investments in third-party vehicles, or co-investment alongside external GPs.

The firm does not publicly maintain an exclusion list or negative sector screen. Its lean public profile and focus on Polish private companies make sector specialization difficult to infer beyond the Avenir Medical Poland exit in medical devices and a relationship with DoxyChain's CEO.

There is no public record of co-investment activity alongside external fund managers. All known deal flows appear founder-anchored, with Słomski taking direct equity positions and governance roles rather than aggregating capital from institutional LPs.